

Ming-Fen Ho

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4194885/publications.pdf>

Version: 2024-02-01

15
papers

233
citations

1040056

9
h-index

1058476

14
g-index

15
all docs

15
docs citations

15
times ranked

337
citing authors

#	ARTICLE	IF	CITATIONS
1	Ketamine and ketamine metabolites as novel estrogen receptor ligands: Induction of cytochrome P450 and AMPA glutamate receptor gene expression. <i>Biochemical Pharmacology</i> , 2018, 152, 279-292.	4.4	35
2	Ketamine and Active Ketamine Metabolites Regulate STAT3 and the Type I Interferon Pathway in Human Microglia: Molecular Mechanisms Linked to the Antidepressant Effects of Ketamine. <i>Frontiers in Pharmacology</i> , 2019, 10, 1302.	3.5	32
3	Estrogen, SNP-Dependent Chemokine Expression and Selective Estrogen Receptor Modulator Regulation. <i>Molecular Endocrinology</i> , 2016, 30, 382-398.	3.7	27
4	Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study. <i>Neuropsychopharmacology</i> , 2021, 46, 2132-2139.	5.4	19
5	Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes. <i>Npj Breast Cancer</i> , 2017, 3, 30.	5.2	18
6	<i>TCL1A</i> Single-Nucleotide Polymorphisms and Estrogen-Mediated Toll-Like Receptor-MYD88-Dependent Nuclear Factor- κ B Activation: Single-Nucleotide Polymorphism and Selective Estrogen Receptor Modulator-Dependent Modification of Inflammation and Immune Response. <i>Molecular Pharmacology</i> , 2017, 92, 175-184.	2.3	18
7	Pharmacogenomic Next-Generation DNA Sequencing: Lessons from the Identification and Functional Characterization of Variants of Unknown Significance in <i>CYP2C9</i> and <i>CYP2C19</i> . <i>Drug Metabolism and Disposition</i> , 2019, 47, 425-435.	3.3	17
8	TSPAN5 influences serotonin and kynurenine: pharmacogenomic mechanisms related to alcohol use disorder and acamprosate treatment response. <i>Molecular Psychiatry</i> , 2021, 26, 3122-3133.	7.9	17
9	<i>SLCO1B1</i> : Application and Limitations of Deep Mutational Scanning for Genomic Missense Variant Function. <i>Drug Metabolism and Disposition</i> , 2021, 49, 395-404.	3.3	17
10	Selective Serotonin Reuptake Inhibitor Pharmacogenomics: Mechanisms and Prediction. <i>Frontiers in Pharmacology</i> , 2020, 11, 614048.	3.5	10
11	TCL1A, a Novel Transcription Factor and a Coregulator of Nuclear Factor κ B p65: Single Nucleotide Polymorphism and Estrogen Dependence. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 365, 700-710.	2.5	9
12	Genome-wide association study for circulating FGF21 in patients with alcohol use disorder: Molecular links between the SNHG16 locus and catecholamine metabolism. <i>Molecular Metabolism</i> , 2022, 63, 101534.	6.5	5
13	Catechol O-Methyltransferase Pharmacogenomics: Challenges and Opportunities. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 281-283.	4.7	4
14	Genetic variants associated with acamprosate treatment response in alcohol use disorder patients: A multiple omics study. <i>British Journal of Pharmacology</i> , 2022, , .	5.4	4
15	Immune Mediator Pharmacogenomics: SNPs and Estrogen-Dependent Regulation of Inflammation. <i>Journal of Nature and Science</i> , 2017, 3, .	1.1	1